Blueprint Medicines Announces FDA Approval of AYVAKIT™ (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor January 9, 2020
Kyruus Raises $42 Million in New Financing After Delivering Another Year of Record Growth January 8, 2020
Apellis Pharmaceuticals’ drug candidate outperforms Alexion’s Soliris in a clinical trial comparing the two January 7, 2020
Sirnaomics and Innovent Entered Strategic Collaboration to Conduct Clinical Oncology Studies Combining STP705 and Sintilimab in the US January 7, 2020